TITLE

FDA actions

PUB. DATE
November 2011
SOURCE
Travel Medicine Advisor;Nov2011 Supplement, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article focuses on the several actions taken by the U.S. Food & Drug Administration (FDA) including issuing a warning concerning the risk for arrhythmia linked with the ondansetron, removal of epinephrine inhaler from the market, and approving infliximab for treating ulcerative colitis.
ACCESSION #
68638048

 

Related Articles

  • FDA actions. Elliott, William T. // Primary Care Reports;Nov2011 Pharmacology Watch, p2 

    The article reports few of FDA actions which include warning against antinausea drug, ondansetron which is linked with arrhythmia; epinephrine inhaler, an over-the-counter inhaler for asthma to be withdrawn from December 31, 2012; and infliximab received FDA approval for treating ulcerative colitis.

  • FDA Actions in brief.  // Managed Healthcare Executive;Mar2005, Vol. 15 Issue 3, p60 

    This article presents news briefs related to the activities of the U.S. Food and Drug Administration. First time generic approvals include bupropion extended-release tablets 200 mg; didanosine delayed-release capsules 200, 250, and 400 mg; quinapril tablets 5,10, 20, and 40 mg; halobetasol cream...

  • FDA actions in brief.  // Formulary;Jun2006, Vol. 41 Issue 6, p264 

    The article presents various drugs approved by the U.S. Food and Drug Administration as of June 2006. Celgene's Thalidomide was approved in combination with dexamethasone for the treatment of patients with newly diagnosed multiple myeloma. The agency also approved Centocor's infliximab Remicade,...

  • New indications.  // Formulary;Nov2006, Vol. 41 Issue 11, p556 

    The article presents information on Remicade, the drug which belongs to the Infliximab group. Remicade has been developed by Centocor Inc. Remicade is a monoclonal antibody, which is approved by the U.S. Food and Drug Administration for the treatment of chronic plaque psoriasis. Infliximab acts...

  • Remicade Approved for Children With Crohn's Disease.  // FDA Consumer;Jul/Aug2006, Vol. 40 Issue 4, p6 

    The article provides information on Remicade (infliximab), a drug approved by the U.S. Food and Drug Administration (FDA) to treat children with active Crohn's disease, a chronic inflammatory condition of the bowel that can be severely debilitating. Remicade is a genetically engineered...

  • News Briefs.  // American Journal of Health-System Pharmacy;9/15/2010, Vol. 67 Issue 18, p1499 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved a new formulation of docetaxel and a needleless intravenous (i.v.) connector with chlorhexidine and silver and zero-fluid displacement.

  • Slew of approvables.  // Drug Topics;11/17/2003, Vol. 147 Issue 22, p27 

    Lists several approval drugs by the U.S. Food and Drug Administration. Ranexa to treat chronic angina; Insulin determir, a long-acting form of the diabetes drug; Fortament, an extended-release product to lower blood glucose.

  • FDA actions in brief.  // Formulary;Feb2010, Vol. 45 Issue 2, p42 

    The article discusses news briefs about drugs approved by the U.S. Food and Drug Administration (FDA). The drugs include dalfampridine extended release tablets, tocilzumab and morphine sulfate oral solution.

  • Pipeline preview.  // Formulary;Apr2010, Vol. 45 Issue 4, p113 

    The article offers U.S. Food & Drug Administration (FDA) drug approval news briefs. Miglustat has been approved for the treatment of Niemann-Pick type C disease, pirfenidone has been recommended for approval to improve lung function and pixantrone has been recommended not to be approved.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics